German firm negotiates license deal over RA drug

10/18/2007 | Bloomberg1

German biotech company 4SC AG is negotiating with several drugmakers to license its drug SC12267 for rheumatoid arthritis, CEO Ulrich Dauer said. The firm says the drug, which targets autoimmune disorders, also has shown promise in treating multiple sclerosis and chronic bowel conditions.

View Full Article in:

Bloomberg1

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Director, Site Quality Management
CareFusion
Minneapolis, MN
In house Compliance Officer
Confidential
Pompano Beach, FL
Clinical Project Manager
Abiomed, Inc.
Danvers, MA
Sr. Manager, Regulatory Affairs - International
Integra LifeSciences
Plainsboro, NJ
Associate - Food and Drug
Keller and Heckman LLP
Washington, DC